NCCN Guidelines and NCCN Compendium Updated
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer. These NCCN Guidelines are currently available as Version 1.2011.
A footnote was added that small bowel and appendiceal adenocarcinoma may be treated with systemic chemotherapy according to the NCCN Guidelines for Colon Cancer.
A preferred listing was added to the FOLFOX regimen in the adjuvant setting for stage III disease.
The combination regimen of capecitabine and oxaliplatin was added as an option in the adjuvant setting for stage III disease with a category 2A designation.
The combination regimen of irinotecan and oxaliplatin was added as an option for patients with advanced or metastatic disease that progresses following initial therapy with 5-FU/leucovorin plus bevacizumab.
The following parameters were added for reporting of pathologic stage: lymphovascular invasion, perineural invasion, and extra nodal tumor deposits.
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Rectal Cancer. These NCCN Guidelines are currently available as Version 1.2011.
For patients with pT3,N0,M0 or pT1-3,N1-2 disease after resection who have not undergone preoperative chemoradiation, capecitabine plus oxaliplatin was added as a category 2A adjuvant chemotherapy option following chemoradiation therapy with continuous 5-FU/RT or bolus 5-FU + leucovorin/RT or capecitabine/RT.
Capecitabine/RT was changed from a category 2B designation to a category 2A designation.
The combination of capecitabine and oxaliplatin was added as an adjuvant chemotherapy option with a category 2A designation for patients with clinical stage T3, N0, Tany, N1-2, or T4 and/or locally unresectable disease following preoperative chemoradiation therapy and surgery.
The combination regimen of irinotecan and oxaliplatin was added as an option for patients with advanced or metastatic disease that progresses following initial therapy with 5-FU/leucovorin plus bevacizumab.
The following parameters were added for reporting of pathologic stage: circumferential resection margin, neoadjuvant treatment effect, lymphovascular invasion, perineural invasion, and extra nodal tumor deposits.
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Anal Carcinoma. These NCCN Guidelines are currently available as Version 1.2011.
The TNM staging system for anal canal cancer has been modified for consistency with the 7th edition of the American Joint Committee on Cancer (AJCC) Staging Manual.
For the complete updated versions of the NCCN Guidelines and the NCCN Compendium visit NCCN.org.
